24,213
Total Claims
$1.9M
Drug Cost
1,818
Beneficiaries
$1,070
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
+2%
Cost per patient vs peers
$1,070 vs $1,054 avg
-22%
Brand preference vs peers
10.2% vs 13.1% avg
Brand vs Generic
90% generic
Brand: 2,474 claims · $1.6M
Generic: 21,739 claims · $314K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 949 | $826K |
| Rivaroxaban | 221 | $207K |
| Sacubitril/Valsartan | 152 | $128K |
| Dapagliflozin Propanediol | 142 | $120K |
| Empagliflozin | 99 | $96K |
| Evolocumab | 88 | $90K |
| Ticagrelor | 80 | $49K |
| Atorvastatin Calcium | 2,398 | $27K |
| Potassium Chloride | 1,212 | $20K |
| Metoprolol Succinate | 1,326 | $19K |
| Rosuvastatin Calcium | 1,438 | $19K |
| Nifedipine | 618 | $18K |
| Clopidogrel Bisulfate | 1,495 | $17K |
| Alirocumab | 15 | $15K |
| Icosapent Ethyl | 35 | $15K |
Prescribing Profile
81
Unique Drugs
$1.4M
Patient Profile
73
Avg Age
58%
Female
1.57
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About